The state has enjoyed success funding and building life sciences companies, and the new Indiana Biosciences Research Institute should give it a further boost, according to panelists Friday at IBJ's Life Sciences Power Breakfast.
Lilly expects to soon announce late-stage clinical trial results for two biotech drugs designed to slow the inflammation caused by autoimmune diseases. By the end of the year, it will announce results for a third.
The individual hospital campuses around Indianapolis saw their collective revenue rise 8 percent and their collective operating profits rise 22 percent from from 2011 to 2013. That's solid, just not stellar, growth.
In Indiana, Anthem has struck accountable care organization deals with 14 health care provider groups and signed up nearly 2,900 primary care providers to its medical home program. And it's pushing for more in the future.
For employer health plans, diabetics generate $10,000 more per year in medical bills than non-diabetics. That means the rise in the prevalence of diabetes over the past 25 years is costing Hoosiers an extra $2.6 billion annually.
Hospital system tripled its profit last year by wooing patients to its physicians, trimming hospital and clinical staff by more than 400. The rating agency Moody's says things look even better in 2015.
Such companies as HealthPro, OkCopay and even large insurers like Anthem are helping doctors and hospitals create new ways to package and price health care services, relieving some of the price-raising effects of traditional health insurance.